These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19776036)

  • 41. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots.
    Aitken SC; Kliphuis A; Bronze M; Wallis CL; Kityo C; Balinda S; Stevens W; Spieker N; de Oliveira T; Rinke de Wit TF; Schuurman R
    J Clin Microbiol; 2013 Jun; 51(6):1899-905. PubMed ID: 23596235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
    Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High efficacy of first-line ART in a West African cohort, assessed by dried blood spot virological and pharmacological measurements.
    de Truchis P; Lê MP; Daou M; Madougou B; Nouhou Y; Moussa Saley S; Sani A; Adehossi E; Rouveix E; Saidou M; Peytavin G; Delaugerre C
    J Antimicrob Chemother; 2016 Nov; 71(11):3222-3227. PubMed ID: 27439522
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings.
    Kumarasamy N; Krishnan S
    Curr Opin HIV AIDS; 2013 Nov; 8(6):586-90. PubMed ID: 24100872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Challenges and opportunities for the implementation of virological testing in resource-limited settings.
    Roberts T; Bygrave H; Fajardo E; Ford N
    J Int AIDS Soc; 2012 Oct; 15(2):17324. PubMed ID: 23078767
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens.
    Marconi A; Balestrieri M; Comastri G; Pulvirenti FR; Gennari W; Tagliazucchi S; Pecorari M; Borghi V; Marri D; Zazzi M
    Clin Microbiol Infect; 2009 Jan; 15(1):93-7. PubMed ID: 19220340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dry Blood Spots a Reliable Method for Measurement of Hepatitis B Viral Load in Resource-Limited Settings.
    Stene-Johansen K; Yaqoob N; Overbo J; Aberra H; Desalegn H; Berhe N; Johannessen A
    PLoS One; 2016; 11(11):e0166201. PubMed ID: 27820845
    [TBL] [Abstract][Full Text] [Related]  

  • 52. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.
    Jordan MR; Bennett DE; Bertagnolio S; Gilks CF; Sutherland D
    Antivir Ther; 2008; 13 Suppl 2():15-23. PubMed ID: 18575188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries.
    Colebunders R; Moses KR; Laurence J; Shihab HM; Semitala F; Lutwama F; Bakeera-Kitaka S; Lynen L; Spacek L; Reynolds SJ; Quinn TC; Viner B; Mayanja-Kizza H
    Lancet Infect Dis; 2006 Jan; 6(1):53-9. PubMed ID: 16377535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Dried blood spots for monitoring HIV infection in Public Health Programs in developing countries].
    De Mulder M; Holguín A
    Enferm Infecc Microbiol Clin; 2013 Feb; 31(2):100-7. PubMed ID: 22560588
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiretroviral drug resistance among HIV-1 infected children failing treatment.
    Mullen J; Leech S; O'Shea S; Chrystie IL; Du Mont G; Ball C; Sharland M; Cottam F; Zuckerman M; Rice P; Easterbrook P
    J Med Virol; 2002 Nov; 68(3):299-304. PubMed ID: 12226814
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
    Cozzi-Lepri A; Phillips AN; Martinez-Picado J; Monforte Ad; Katlama C; Eg Hansen AB; Horban A; Bruun J; Clotet B; Lundgren JD;
    J Infect Dis; 2009 Sep; 200(5):687-97. PubMed ID: 19604043
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
    Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
    Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of dried-blood-spot samples and in-house assays to identify antiretroviral drug resistance in HIV-infected children in resource-constrained settings.
    Ziemniak C; Mengistu Y; Ruff A; Chen YH; Khaki L; Bedri A; Simen BB; Palumbo P; Eshleman SH; Persaud D
    J Clin Microbiol; 2011 Dec; 49(12):4077-82. PubMed ID: 21956987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.